R&D The value of unstructured data for drug companies Advancements in medical AI now allow pharmaceutical companies to leverage unstructured clinical data at scale.
R&D Navigating the unique challenges of epilepsy in women's heal... Epilepsy affects women differently than men, owing to the complexity of brain health and the historical lack of investment in women’s health.
R&D The glimmer of opportunity behind the storm: Ali Pashazadeh ... Former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, discusses the current ‘perfect storm’ in biotech.
R&D The impact of generative AI on protein design for drug disco... Artificial Intelligence (AI) is at the heart of the latest global transformation, not least within the biopharmaceutical industry.
R&D Changing the drug development treatment paradigm: Hilary Eat... Hilary Eaton, a rare disease advocate and chief business officer at Profluent, discusses AI-first protein design and accelerating biomedicine.
R&D How Europe can harness the full potential of biosimilars Biosimilars - clinically equivalent alternatives to original biologic drugs - play a vital role in addressing unmet health needs.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
